Clinical Trials | March 11, 2026
Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
Giredestrant shows promise despite missing primary goal
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Germany will be the first launch market
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Subscribe To Our Newsletter & Stay Updated
